Is there a risk of CYP2C19 gene testing only being adopted by wealthier health systems, thereby creating a disparity gap in treatment?
What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicability of the results of the CHANCE-2 trial (Wang et al., PMID 34708996)?
Answer from: at Academic Institution
It is likely that CYP2c19 metabolizer status will be available in better-resourced health care systems unless the testing becomes widely available with a quick turnaround and is inexpensive.
Answer from: at Community Practice
It is likely that both genetic testing and ticagrelor treatment will only be adopted in wealthier countries and with wealthier individuals in those countries. This is likely to exacerbate current inequity in stroke care and outcomes. That being said, there is substantial room for improvement in trea...
Agreed. Platelet reactivity is the most often util...